Poll: Do you believe biosimilars have the same efficacy as branded medications?

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

Survey: Awareness of biosimilars for retinal diseases in the US and Europe

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Health policy implications for biosimilars: getting to the heart of the matter

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

Ranibizumab biosimilar to launch in US

September 22, 2022

Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.